## ALBERTA PRECISION LABORATORIES

DATE:	2021 August 23
то:	All AHS Zones, Physicians / Nurses / Managers; APL Managers, Supervisors, and Medical/Scientific Staff
FROM:	Chemistry and Point of Care Testing (POCT), Alberta Precision Laboratories
RE:	Change in Abbott i-STAT1 Conventional Troponin I Cut-off

# PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

#### Key Message

- Effective August 23, 2021, the Abbott i-STAT1 conventional cardiac troponin I (TnI) positivity cut-off value will be lowered from 0.10 μg/L to 0.04 μg/L. Results will only be reported in conventional units of μg/L.
- The Abbott i-STAT1 conventional Tnl will have new reporting comments.

#### Background

- This change in cut-off value is literature-based, including a study in Alberta that showed a strong correlation between Abbott i-STAT1 conventional Tnl values of equal to or greater than 0.04 µg/L and the Tnl 99<sup>th</sup> percentile cut-off used for several of the Tnl assays found in the province. An Abbott i-STAT1 conventional Tnl positivity cut-off of 0.04 µg/L has been adopted at other institutions in Canada.
- Three sets of new reporting comments will accompany the results as follows:

Current Reporting	NEW Reporting		
Troponin ≤0.10 μg/L	<b>Troponin I ≤0.04 μg/L</b> Troponin I value not consistent with acute myocardial		
In a clinical setting consistent with ACS, TnI > 0.10 ug/L is consistent with myocardial injury whereas	infarction, providing the sample was collected more than 6h from onset of symptoms.		
peak Tnl < or = 0.10 ug/L is consistent with myocardial ischemia without injury. Tnl > 0.10 ug/L may be observed in	Repeat troponin testing 6 to 8 hours after the initial sample is recommended for all patients to reliably exclude myocardial infarction.		
several nonthrombotic cardiac and systemic diseases (most commonly - acute PE, acute pericarditis, acute or severe HF, myocarditis, sepsis and/or shock).	Please note that patients with ischemic ECG changes and/or high-risk clinical presentations should be further evaluated irrespective of troponin results.		
	Troponin I 0.05 –0.10 μg/L (High)		
	Troponin I value is inconclusive for acute myocardial infarction and may be due to myocardial injury.		
	Repeat troponin testing 6 to 8 hours after the initial sample is recommended for all patients to reliably exclude myocardial infarction.		

Please note that patients with ischemic ECG changes and/or high-risk clinical presentations should be considered for further evaluation irrespective of troponin results.
Troponin >0.10 μg/L (High)
Clear elevation of Troponin I consistent with acute myocardial injury or infarction in the appropriate clinical
context.
Repeat troponin testing 6 to 8 hours after the initial
sample may be helpful to assess for ongoing myocardial injury.
injury.
Tnl >0.10 ug/L may be observed in several nonthrombotic
cardiac and systemic diseases (most commonly - acute PE,
acute pericarditis, acute or severe HF, myocarditis, sepsis and/or shock).
All Results:
Method Used: i-STAT conventional troponin I. WARNING:
Different methods give potentially significantly different numerical values. Do not compare results from method to method

#### How this will impact you

- Myocardial injury or infarction should no longer be excluded in patients with an Abbott i-STAT1 conventional Tnl result equal to or lower than 0.10 μg/L.
- Patients with an i-STAT1 conventional Tnl value of 0.05-0.10 μg/L may have myocardial injury or early myocardial infarction in the appropriate clinical setting.
- Results above 0.1 µg/L in <u>outpatients</u> will be phoned to the ordering physician.

## Action Required

- Be aware of these reporting changes and understand how they will impact clinical management. This change applies to results performed by POCT or laboratory with Abbott i-STAT1 conventional Tnl.
- Patients with any Abbott i-STAT1 conventional TnI result equal to or lower than 0.10 µg/L may require further follow-up including repeat Abbott i-STAT1 conventional TnI testing at 6-8 hours.
- Ensure all instrument related configurations and software settings, and related program (procedure and reporting) documents have been updated.
  If performing as POCT, refer to the Abbett i STAT1 and i STAT Alimity Meters Upsite
  - $_{\odot}$  If performing as POCT, refer to the <u>Abbott i-STAT1 and i-STAT Alinity Meters | Insite</u>

## Effective

• August 23, 2021

## **Questions/Concerns**

- Jessica Gifford, PhD, Clinical Biochemist, South Sector, 403-770-3779, <u>Jessica.Gifford@aplabs.ca</u>
- Mireille Kattar, MD, Consultant Pathologist, North Sector, 780-407-3373, Mireille.Kattar@aplabs.ca

- Isolde Seiden Long, PhD, Clinical Biochemist, South Sector, 403-944-3993, Isolde.SeidenLong@aplabs.ca
- Albert Tsui, PhD, Clinical Biochemist, North Sector, 587-782-2674, Albert.Tsui@aplabs.ca
- Yury Butorin, PhD, Clinical Biochemist, South Sector, 403-406-5633, Yury.Butorin@aplabs.ca
- Zone POCT Team:

Calgary:	Central:	Edmonton:	North:	South:
POCT.Calgary@aplabs.ca	poc.centralzone@ahs.ca	poccertification@ahs.ca	pointofcare.northzone@ahs.ca	poc.centralzone@ahs.ca

### Approved by

- Kareena Schnabl, PhD, Clinical Section Chief, Clinical Biochemistry, North Sector, APL
- Hossein Sadzadeh, PhD, Clinical Section Chief, Clinical Biochemistry, South Sector, APL
- Allison Venner, PhD, Provincial POCT Medical Lead, APL
- Michael Mengel, MD, North Sector Medical Director, APL
- Leland Baskin, MD, South Sector Medical Director, APL